Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 13/20 | 0.49 |
| ▸ | AVPR1A | P37288 | 13/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8232623 | 0.89 | AVPR2 (0.51) | AVPR2AVPR1ACNR1 | |
| SCHEMBL8234803 | 0.87 | AVPR2 (0.52) | AVPR2AVPR1ACNR1TRPA1 | |
| SCHEMBL8237655 | 0.86 | AVPR2 (0.48) | AVPR2AVPR1ACNR1TRPA1 | |
| SCHEMBL14476689 | 0.86 | AVPR2 (0.49) | AVPR2AVPR1ACNR1 | |
| SCHEMBL8233201 | 0.86 | AVPR2 (0.51) | AVPR2AVPR1ACNR1GPR139 | |
| SCHEMBL12057175 | 0.85 | AVPR2 (0.52) | AVPR2AVPR1ACNR1 | |
| SCHEMBL12057379 | 0.85 | AVPR2 (0.49) | AVPR2AVPR1ACNR1LMNA | |
| SCHEMBL8233236 | 0.85 | AVPR2 (0.50) | AVPR2AVPR1ACNR1TRPA1 | |
| SCHEMBL4513232 | 0.85 | AVPR2 (0.59) | AVPR2AVPR1ACNR1 | |
| SCHEMBL8234738 | 0.85 | AVPR2 (0.49) | AVPR2AVPR1ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027096-B1 | SUBSTITUTED ARYLIMIDAZ0L0NE AND TRIAZ0L0NE AS INHIBITORS OF VASOPRESSIN RECEPTORS | Bayer Pharma AG (DE) | 2012-05-23 | — | — | EP | disclosed |